Answer
Nucala (mepolizumab) is indicated as add-on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype on combined inhaled corticosteroid, long-acting beta2-agonist and long-acting muscarinic antagonist therapy.
Sources for this answer
- Nucala 100 mg solution for injection in pre-filled penGlaxoSmithKline UK · emc · SmPC §4.1 Therapeutic Indications · Version 11Document updated
Sources checked